Meeting daily compliance in PharmaOperations



Similar documents
MeriCal Quality Profile

NEW CHEMICAL ENTITIES

Extemporaneously Prepared Early Phase Clinical Trial Materials

Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE

Combination Products. Presented by: Karen S. Ginsbury For: IFF March PCI Pharma

Quality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:

2014 Annual Report on Inspections of Establishments

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Audit Report in the framework of the APIC Audit Programme

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

Auditing as a Component of a Pharmaceutical Quality System

Pharmaceutical Quality Systems: US Perspective

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation

Life (or is it really?) Under a Consent Decree

Welcome to the ChemCon Company Presentation: 6 Steps to Success for our Customers!

Sandoz Private Limited 10/22/15

C 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to


Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

1. Scope This SOP covers requirements for PHARMCO-AAPER s Quality Management System

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY VERSION 7

Best Practices In Ensuring Quality Standards When Outsourcing To Contract Manufacturers, Licensees And Consultants

Recent Updates on European Requirements and what QPs are expected to do

Harmonizing Change Control Processes Globally

Pharmaceutical Wholesaler Site Inspection Checklist

Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant

The FDA recently announced a significant

What is the correct title of this publication? What is the current status of understanding and implementation?

GRADUATE CERTIFICATE IN GOOD MANUFACTURING PRACTICE (GMP) Plan your career for tomorrow and you will be ahead of your competitors

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)

Clinical Trial Logistics

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

CONCEPT HEIDELBERG. Pharmaceutical Quality Training. Conferences. Services.

Engineering Nanomedical Systems

Annex 9 Guide to good storage practices for pharmaceuticals 1

Quality Management System for Active pharmaceutical Ingredients manufacturers. Integrating GMP into ISO 9001

Supply Chain Challenges and Risk Management

Microbiology and Auditing. Don Singer

The Quality System for Drugs in Germany

Conducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.

Inspections, Compliance, Enforcement, and Criminal Investigations

Guide to Master Formulae WHO/FWC/IVB/QSS/VQR

Library Guide: Pharmaceutical GMPs

Good Manufacturing Practices: A Synopsis of Their Role and Rationale in Today's Pharmaceutical Marketplace for Tubing

FOOD AND DRUG LAW JOURNAL Analyzing the Laws, Regulations, and Policies Affecting FDA-Regulated Products

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

Principles. of Pharmaceutical Facility Design. Full Time Part Time Online.

ASI 691 Prinicples of HACCP 1

GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS

GMP Regulatory Considerations

ICH Public Meeting. Joseph C. Famulare. October 2, Acting Deputy Director Office of Compliance CDER / FDA Office of Compliance

Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables

FDA Inspection Observations The FDA 483 and Beyond. Objectives

Planning Engineering Projects management of Pharmaceutical Plants

Monitoring manufacturing, production and storage environments in the pharmaceutical industry

Guidance for Industry

How companies leverage quality and quality certifications to achieve competitive advantage

COTS Validation Post FDA & Other Regulations

Impact of Formula-Based ERP Applications on Pharmaceutical Manufacturers

Pharmaceutical Quality Management System: Current Concept

Validation Consultant

Documenting Distribution Operations: FDA Validation Beyond the Laboratory and Manufacturing Facility

New Investigator Collaborations and Interactions: Regulatory

Overview of Pre-Approval Inspections

10 common GMP challenges facing Maintenance departments in pharmaceutical plants

PHARMACEUTICAL REFERENCE STANDARDS

On-Site GMP Training GMP COMPLIANCE TECHNICAL

FDA 21 CFR Part 11 Electronic records and signatures solutions for the Life Sciences Industry

Corrective and Preventive Actions

World Health Organization Prequalification of Medicines

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

There is no Silver Bullet to complying with the US FDA GMPs by Alan Schwartz

Valentina Gualato, Ph.D. Process Development Scientist

Managing the Cost of Compliance in Pharmaceutical Operations 1

PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7: NON-STERILE PROCESS VALIDATION

COMMISSION DIRECTIVE 2003/94/EC

Jeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Terri Dodds CAPT. (RET) TERRI L.

Corden Pharma Latina S.p.A. 5/20/16

Making SOP Training More Effective

Guidance on Qualification of existing facilities, systems, equipment and utilities

B i o s o l u t i o n s

Regulation and Risk Management of Combination Products

We are the regulator: Our job is to check whether hospitals, care homes and care services are meeting essential standards.

(COMPANY LOGO) CGMP COMPUTERIZED SYSTEM VENDOR AUDIT QUESTIONNAIRE

Lean Process Improvements for the GMP Laboratory

Timeworks Manufacturing Services

JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS

Providing Trusted and Innovative Solutions t o the Life Science Communities

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients

Cleaning and Contamination Control

Validation Approach and Scope for Business Process System Validation. Epitome Technologies Private Limited

DISCUSSION TOOL PRESENTED TO THE AABB CT REGULATORY AFFAIRS SUBSECTION

CUSTOM PEPTIDE SYNTHESIS AT BACHEM

Impact of Formula-Based ERP Applications on Chemical Manufacturers

Annex 7 Guidelines on pre-approval inspections

Welcome Computer System Validation Training Delivered to FDA. ISPE Boston Area Chapter February 20, 2014

Transcription:

Meeting daily compliance in PharmaOperations SKMF Spring Event 2012 Dr. Peter Hess

Themenübersicht Compliance Framework GMP Activities and compliance documentation in a production plant Compliance preconditions «The way» to compliance Intangible assets and value creation The missink link

Pharma Compliance in the Press Reuters, Dec 6, 2011: FDA cites violations at three Novartis plants (Reuters) -Drug regulators cited Novartis AG for "significant violations" of manufacturing regulations at its three generic drug plants in the United States and Canada, several of which were repeat offenses. "We are concerned that your firm lacks process understanding to consistently manufacture", FDA wrote in the letter dated November 18. US department of Health & Services/FDA; Jan 8 2012: Novartis is voluntarily recalling all lots of two products / Novartis commitment to quality Novartis Consumer Health, Inc. (NCH) announced today that it is voluntarily recalling all lots of select bottle packaging configurations of Excedrin and NoDoz products because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets. The Novartis Group is fully committed to ensuring the quality, safety and integrity of its products. All Novartis Group companies have a clear commitment to patients and Health Authorities to ensure high quality standards for all our products and services. Pharma Manufacturing Newsletter February 6, 2012: FDA report shows deep problems at closed Novartis Consumer Health plant. Novartis has set aside $120 million to address shortcomings at the plant and CEO Joseph Jimenez has told the investment community he is confident the plant will reopen mid-year.

Compliance Framework in the Pharma Industry Ultimate goals of compliance: Safeguarding the health of the patient as well as producing good quality medicine, medical devices or active pharmaceutical products. cgmp (CurrentGood Manufacturing Practice): Main mandatory regulation for Pharma Industry anchored in the US federal Food, Drug, and Cosmetic (FD&C) Act and EudraLex Volume 4 in EU. "GMP" -A set of principles and procedures which, when followed by manufacturers for therapeutic goods, helps ensure that the products manufactured will have the required quality. A basic tenet of cgmp is that quality must be built into each batch of product during all stages of the manufacturing process. cgmp is that part of Quality Assurance aimed at ensuring that products are consistently manufactured to a quality appropriate to their intended use Compliance Monitoring & Enforcement: Inspections performed by national Regulatory Agencies like CH: Swissmedic, US: FDA, EU: DG Health & Consumers). Regulatory agencies are authorized to conduct unannounced inspections at any time the firms are open for business.

GMP covers. ALLaspects of production; from the starting materials, premises and equipment to the training and personal hygiene of staff. Documents: Detailed, written procedures are essential for each process that could affect the quality of the finished product. Document Management: There must be systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process -every time a product is made. Quality management system (QMS): Each company has to create own individual QMS which integrates cgmp requeirements but covers and integrates manyother (national) regulations, quidelines, internal policies. Qualification requirements ( 211.25 ): Each person engaged or responsible for supervising in the manufacture, processing, packing, or holding of a drug product shall have education, training, and experience, or any combination thereof, to enable that person to perform the assigned functions. Management approach: «The parameters and requirements to achieve compliance are given, let s do it «How do companies manage all that know-how Dr. Hess Interim How can Management all employees know at any time what and how to do Umfassende Kompetenz Responsibilities in Logistik und Produktion and

Compliance Management Systems But: is that all.?

Overview activities in production plant Synthesis of final Product (API) : Several chemical stages required Products are manufactured in campaigns with multiple product lines configured to operate simultaneously. Parallel to the production: cleaning (product change), maintenance (repair, qualification, calibration). Summary: Dozens of different activities take place at the same time. A single stage SM1 IP1 SM2 API KI IP2 SM3 Handling Loading Process Work Up Isolation Sampling dispensing weighing of materials Solvents reagents intermediates chemical reaction step quench evaporation filtration extraction/ phase separation crystallisation filtration centrifugation drying milling sieving blending

Compliance: Overview important documents Regulated Areas Activities Documentation Buildings Infrastructure Process Equipment Control Systems Documentation Hygiene Manufacturing Utilities Tank Farm Warehouse QC Personel Security & Safety Process work Monitoring Cleaning Validation Calibration Qualification Sampling Staff Training Policies SOP Specifications Master Formula Record Batch MR Manuals Master plans/ files Validation protocols Forms and Formats Records Policies SOP Specifications MFR (Master Formula Record) Batch MR Manuals Master plans/ files Validation protocols Forms Policies SOP Specifications Master Formula Record Batch MR Manuals Master plans/ files Validation protocols Forms and Formats Records How can all employees know at any time what and how to do?

Compliance Preconditions Novartis non-compliance?? GMP Compliance Compliance happens all the time, everywhere with every action: How can a plant manager guarantee and account for compliance relying on many Individuals? How to achieve compliance? Zero Error Culture Operational Excellence Something missing? Experience, Further learning Training on the job, SOP s, Practical GMP-raining GMP Theory, Company Guidelines, Education All management & staff levels Willngness Ability Knowledge Information

The «way» to compliance «Complience Rules» «The Way» Enforcement? Empowerment? Control? Trust? «The Goal»???

The «way» to compliance «Complience Rules» «The Way»?

The «way» to compliance «Complience Rules» «The Way»?

The «way» to compliance «Complience Rules» «The Way»?

Intangible assets and value creation Goal of Knowledge Management*) «A systematic approach to find, understand, share and use knowledge to cretae value» Pharmaceutical industry Knowledge based organizations with focus on operational excellence (= processes, quality & costs) use best practice by sharing knowledge Individual / intangible Assets = The true foundation of value creation are the intangible assets of the companies = Knowledge and Abilities of the managers, middle managers and frontline employees Leadership Willingness and Motivation Value Creation The ability to craete value depends not on written proceders and quiedelines, but on the willingens and motivation of individuals to focus on their daily work, to reach their daily goals and all compliance requierements *) Carla O'dell, C. Jackson Grayson, If Only We Knew What We Know, pioneers in Knowledge Management

Summary: The missing link The ability to craete value depends not on written proceders and quiedelines, but on the willingness of individuals to focus on their daily work, to reach their daily goals and all compliance requierements GMP Compliance Zero Defect Culture Operational Excellence Skills, Behavior, Cultur Experience, Learning Training on the job, SOP s, Practical Training The ultimate driver for business success i.e. compliance is to transform knowledge and ability into willingness and motivation of each individual and his performance Motivation Ability Knowledge Company Guidelines, Education, GMP Theory, Information

The most ancient and simple compliance approach! Epicurus, 341-270 BC, is one of the well known writers of antiquity. The central point of his thinking was linked to the question: On what relies the happiness of the wise man? Epicurus replies (fully in the meaning of GMPcompliance): The wise man arranges his life according to rules to relieve him from of fear, pain and desire

Vielen Dank! Fragen?